ASCO 2021 | VISION trial: future research

Considering the results from the VISION trial (NCT03511664), Karim Fizazi, MD, PhD, Institut Gustave Roussy, Villejuif, France, discusses future research concerning 177Lu-PSMA-617 in prostate cancer. The VISION trial used patients with advanced metastatic castration-resistant prostate cancer (mCRPC), hence future research may consider the efficacy and safety of 177Lu-PSMA-617 in earlier stages of prostate cancer; a trial is beginning examining the efficacy of 177Lu-PSMA-617 in patients who have failed treatment with androgen receptor (AR) drugs but are yet to undergo chemotherapy. Moreover, another new trial is set to examine the efficacy of 177Lu-PSMA-617 in de novo metastatic prostate cancer, prior to treatment with androgen deprivation therapy (ADT) and AR drugs. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.